Terms: = Prostate cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4
106 results:
1. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
Oncogene; 2024 Jan; 43(1):22-34. PubMed ID: 37875657
[TBL] [Abstract] [Full Text] [Related]
2. GATA2 co-opts TGFβ1/smad4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
Yang X; Zhang Q; Li S; Devarajan R; Luo B; Tan Z; Wang Z; Giannareas N; Wenta T; Ma W; Li Y; Yang Y; Manninen A; Wu S; Wei GH
J Exp Clin Cancer Res; 2023 Aug; 42(1):198. PubMed ID: 37550764
[TBL] [Abstract] [Full Text] [Related]
3. SMAD3 promotes expression and activity of the androgen receptor in prostate cancer.
Jeon HY; Pornour M; Ryu H; Khadka S; Xu R; Jang J; Li D; Chen H; Hussain A; Fazli L; Gleave M; Dong X; Huang F; Wang Q; Barbieri C; Qi J
Nucleic Acids Res; 2023 Apr; 51(6):2655-2670. PubMed ID: 36727462
[TBL] [Abstract] [Full Text] [Related]
4. Dibutylstannanediyl (2Z,2'Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/smad4 signaling.
Waseem D; Khan GM; Haq IU; Syed DN
Toxicol Appl Pharmacol; 2022 Aug; 449():116127. PubMed ID: 35705140
[TBL] [Abstract] [Full Text] [Related]
5. PELO facilitates PLK1-induced the ubiquitination and degradation of smad4 and promotes the progression of prostate cancer.
Gao P; Hao JL; Xie QW; Han GQ; Xu BB; Hu H; Sa NE; Du XW; Tang HL; Yan J; Dong XM
Oncogene; 2022 May; 41(21):2945-2957. PubMed ID: 35437307
[TBL] [Abstract] [Full Text] [Related]
6. Racial and Ethnic Disparities in the Use of prostate Magnetic Resonance Imaging Following an Elevated prostate-Specific Antigen Test.
Abashidze N; Stecher C; Rosenkrantz AB; Duszak R; Hughes DR
JAMA Netw Open; 2021 Nov; 4(11):e2132388. PubMed ID: 34748010
[TBL] [Abstract] [Full Text] [Related]
7. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis of Silica Based Nanoparticles Against the Proliferation of Human prostate cancer.
Durmus IM; Deveci I; Karakurt S
Anticancer Agents Med Chem; 2021; 21(18):2553-2562. PubMed ID: 33557739
[TBL] [Abstract] [Full Text] [Related]
9. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient prostate cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.
He L; Fang H; Chen C; Wu Y; Wang Y; Ge H; Wang L; Wan Y; He H
Medicine (Baltimore); 2020 Apr; 99(15):e19760. PubMed ID: 32282738
[TBL] [Abstract] [Full Text] [Related]
11. prostate cancer screening: what do men know, think and do about their risk? exploring the opinions of men in an urban area in Lagos State, Nigeria: a mixed methods survey.
Ugochukwu UV; Odukoya OO; Ajogwu A; Ojewola RW
Pan Afr Med J; 2019; 34():168. PubMed ID: 32153708
[TBL] [Abstract] [Full Text] [Related]
12. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract] [Full Text] [Related]
13. Up-regulation of TIF1γ by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway.
Qi G; Lu G; Yu J; Zhao Y; Wang C; Zhang H; Xia Q
Eur J Pharmacol; 2019 Oct; 860():172551. PubMed ID: 31323225
[TBL] [Abstract] [Full Text] [Related]
14. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract] [Full Text] [Related]
15. IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-β signaling pathway.
Liu X; Chen L; Fan Y; Hong Y; Yang X; Li Y; Lu J; Lv J; Pan X; Qu F; Cui X; Gao Y; Xu D
Cell Death Dis; 2019 Jul; 10(7):517. PubMed ID: 31273201
[TBL] [Abstract] [Full Text] [Related]
16. The metastasis suppressor CD82/KAI1 represses the TGF-β
Lee MS; Lee J; Kim YM; Lee H
Prostate; 2019 Sep; 79(12):1400-1411. PubMed ID: 31212375
[TBL] [Abstract] [Full Text] [Related]
17. Hsa_Circ_0001206 is downregulated and inhibits cell proliferation, migration and invasion in prostate cancer.
Song Z; Zhuo Z; Ma Z; Hou C; Chen G; Xu G
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2449-2464. PubMed ID: 31198063
[TBL] [Abstract] [Full Text] [Related]
18. Relationship between ETS Transcription Factor ETV1 and TGF-β-regulated SMAD Proteins in prostate cancer.
Oh S; Shin S; Song H; Grande JP; Janknecht R
Sci Rep; 2019 Jun; 9(1):8186. PubMed ID: 31160676
[TBL] [Abstract] [Full Text] [Related]
19. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant prostate cancers.
Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
[TBL] [Abstract] [Full Text] [Related]
20. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Feng S; Cheng X; Zhang L; Lu X; Chaudhary S; Teng R; Frederickson C; Champion MM; Zhao R; Cheng L; Gong Y; Deng H; Lu X
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10094-10099. PubMed ID: 30232256
[TBL] [Abstract] [Full Text] [Related]
[Next]
